Results 81 to 90 of about 199,627 (273)

A Bibliometric Analysis of Publications on University-Industry Collaboration Using VOSviewer and R-biblioshiny

open access: yesMultidisciplinary Journal for Education, Social and Technological Sciences
This bibliometric analysis studied the development trends, publication and citation counts, research themes and trends, and international cooperation models related to university-industry collaboration from 1970 to 2023.
Zhan Guofang   +2 more
doaj   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

open access: yesMolecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad   +17 more
wiley   +1 more source

FRONT MATTER

open access: yesJurnal Ilmiah Islam Futura, 2023
Anton Widyanto
doaj   +3 more sources

Knowledge Integration and Diffusion: Measures and Mapping of Diversity and Coherence

open access: yes, 2014
I present a framework based on the concepts of diversity and coherence for the analysis of knowledge integration and diffusion. Visualisations that help understand insights gained are also introduced. The key novelty offered by this framework compared to
A Skupin   +50 more
core   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

open access: yesMolecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande   +11 more
wiley   +1 more source

BACK MATTER

open access: yesJurnal Ilmiah Islam Futura, 2023
Anton Widyanto
doaj   +3 more sources

Aggressive prostate cancer is associated with pericyte dysfunction

open access: yesMolecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero   +11 more
wiley   +1 more source

O uprawnieniu do odrzucenia skargi o stwierdzenie niezgodności z prawem prawomocnego orzeczenia przez sąd powszechny. Glosa krytyczna do postanowienia Sądu Najwyższego z dnia 23 czerwca 2020 r., II CZ 21/20 [PDF]

open access: yesKrytyka Prawa
Przedmiotem niniejszego komentarza jest orzeczenie Sądu Najwyższego – Postanowienie Sądu Najwyższego – Izby Cywilnej z dnia 23 czerwca 2020 r. (sygn. akt: II CZ 21/20), w którym to Sąd Najwyższy wyraził pogląd, zgodnie z którym w zakres pojęcia „innych ...
Paulina Woś
doaj   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

open access: yesMolecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard   +12 more
wiley   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy